The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
Elemental formula supplements showed no clear difference in withdrawals due to adverse events compared with polymeric formula supplements (low certainty).
It is very uncertain whether anti‐TB therapy changes withdrawals due to adverse events compared with placebo (very low certainty).
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).
It is very uncertain whether azathioprine and infliximab changes withdrawals due to adverse events compared with infliximab (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with placebo (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with mesalazine or sulfasalazine (very low certainty).
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
Two infusions of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).